share_log

Exicure | 10-Q: Q1 2024 Earnings Report

Exicure | 10-Q: Q1 2024 Earnings Report

Exicure | 10-Q：2024财年一季报
美股SEC公告 ·  2024/06/18 04:32

Moomoo AI 已提取核心信息

Exicure reported Q1 2024 financial results, with revenue of $0.5 million from a patent license agreement and a net loss of $0.8 million, compared to a net loss of $4.4 million in Q1 2023. Cash and cash equivalents stood at $0.4 million as of March 31, 2024, down from $0.8 million at year-end 2023.The company continues to explore strategic alternatives after suspending all research and development activities. General and administrative expenses decreased 57% to $1.3 million, while research and development expenses were reduced to zero following the suspension of clinical programs. In February 2024, Exicure entered into a patent license agreement for its cavrotolimod asset in hepatitis treatment.Management expressed substantial doubt about the company's ability to continue as a going concern, citing the need for immediate additional funding. The company faces multiple Nasdaq listing compliance issues and received a delisting determination notice in May 2024, which it has appealed with a hearing scheduled for July 2024. Two promissory notes totaling $1 million were secured in May and June 2024 to provide short-term funding.
Exicure reported Q1 2024 financial results, with revenue of $0.5 million from a patent license agreement and a net loss of $0.8 million, compared to a net loss of $4.4 million in Q1 2023. Cash and cash equivalents stood at $0.4 million as of March 31, 2024, down from $0.8 million at year-end 2023.The company continues to explore strategic alternatives after suspending all research and development activities. General and administrative expenses decreased 57% to $1.3 million, while research and development expenses were reduced to zero following the suspension of clinical programs. In February 2024, Exicure entered into a patent license agreement for its cavrotolimod asset in hepatitis treatment.Management expressed substantial doubt about the company's ability to continue as a going concern, citing the need for immediate additional funding. The company faces multiple Nasdaq listing compliance issues and received a delisting determination notice in May 2024, which it has appealed with a hearing scheduled for July 2024. Two promissory notes totaling $1 million were secured in May and June 2024 to provide short-term funding.
生物技术公司Exicure报告称，2024年第一季度净亏损为829,000美元，相比2023年同期的440万美元净亏损显著改善。该季度该公司的营业收入为50万美元，与前年同期没有营业收入形成鲜明对比。这一收入来自于一项针对肝炎的专利许可协议。营业费用减少了71%，从2023年第一季度的450万美元降至130万美元，主要是由于在2022年9月宣布暂停研发活动和裁员。截至2024年3月31日，Exicure的现金及现金等价物为0.4万美元，较2023年年底的0.8万美元下降。该公司的财务状况仍然不稳定，存在重大疑虑，需要在短期内获得额外资金才能继续经营。Exicure正在积极探索战略替代方案，包括...展开全部
生物技术公司Exicure报告称，2024年第一季度净亏损为829,000美元，相比2023年同期的440万美元净亏损显著改善。该季度该公司的营业收入为50万美元，与前年同期没有营业收入形成鲜明对比。这一收入来自于一项针对肝炎的专利许可协议。营业费用减少了71%，从2023年第一季度的450万美元降至130万美元，主要是由于在2022年9月宣布暂停研发活动和裁员。截至2024年3月31日，Exicure的现金及现金等价物为0.4万美元，较2023年年底的0.8万美元下降。该公司的财务状况仍然不稳定，存在重大疑虑，需要在短期内获得额外资金才能继续经营。Exicure正在积极探索战略替代方案，包括潜在的合作伙伴和与其历史业务无关的交易。该公司还经历了与CBI USA及其附属公司DGP获得其普通股的重大变化。由于未遵守多个上市要求，包括最低买盘价和股东权益，Exicure面临着从纳斯达克摘牌的风险。该公司已经上诉摘牌决定，正在等待于2024年7月9日举行的听证会。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Portage Biotech
    PRTG
    -- 9.600
    莱斯康制药
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点